Technical Analysis for RLAY - Relay Therapeutics, Inc.

Grade Last Price % Change Price Change
D 34.11 -6.85% -2.51
RLAY closed down 6.85 percent on Friday, October 15, 2021, on 1.27 times normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Up
Historical RLAY trend table...

Date Alert Name Type % Chg
Fell Below 200 DMA Bearish 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
50 DMA Support Bullish -6.85%
Crossed Above 200 DMA Bullish -6.85%
Crossed Above 20 DMA Bullish -6.85%
MACD Bullish Signal Line Cross Bullish -6.85%
Pocket Pivot Bullish Swing Setup -6.85%
Volume Surge Other -6.85%
Wide Bands Range Expansion -6.85%
Older End-of-Day Signals for RLAY ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible Inside Day 3 days ago
60 Minute Opening Range Breakdown 3 days ago
Down 5% 3 days ago
Down 1 ATR 3 days ago
Down 3% 3 days ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Relay Therapeutics, Inc. Description

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its product candidates include RLY-1971, an oral small molecule inhibitor of the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 (SHP2) that is in Phase 1 dose escalation studies in patients with advanced or metastatic solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2) for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Solid Tumors Drug Discovery Enzymes Precision Medicine Tyrosine Kinase Receptors Tyrosine Kinase Advanced Solid Tumors Fibroblast Growth Factor Fibroblast Growth Factor Receptor Metastatic Solid Tumors Fibroblast Growth Factor Receptor 2 Ptpn11

Is RLAY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 64.0
52 Week Low 25.72
Average Volume 929,775
200-Day Moving Average 36.26
50-Day Moving Average 32.80
20-Day Moving Average 32.82
10-Day Moving Average 30.35
Average True Range 2.94
ADX 27.87
+DI 30.53
-DI 19.63
Chandelier Exit (Long, 3 ATRs) 29.32
Chandelier Exit (Short, 3 ATRs) 34.55
Upper Bollinger Bands 40.34
Lower Bollinger Band 25.30
Percent B (%b) 0.59
BandWidth 45.81
MACD Line -0.46
MACD Signal Line -0.81
MACD Histogram 0.3449
Fundamentals Value
Market Cap 3.07 Billion
Num Shares 90 Million
EPS -0.99
Price-to-Earnings (P/E) Ratio -34.45
Price-to-Sales 0.00
Price-to-Book 6.58
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 39.33
Resistance 3 (R3) 39.62 38.18 38.46
Resistance 2 (R2) 38.18 36.85 38.03 38.17
Resistance 1 (R1) 36.14 36.03 35.42 35.85 37.88
Pivot Point 34.70 34.70 34.34 34.55 34.70
Support 1 (S1) 32.66 33.37 31.94 32.37 30.34
Support 2 (S2) 31.22 32.55 31.07 30.05
Support 3 (S3) 29.18 31.22 29.76
Support 4 (S4) 28.89